[{"Abstract":"Tumor infiltrating lymphocytes (TILs) per high-power field (HPF) as measured by expert pathologists is a useful, independent, validated prognostic marker in colorectal cancer (CRC). Artificial intelligence (AI) techniques of deep learning (DL) can predict TILs directly from routinely collected, digitized hematoxylin and eosin (H&#38;E) pathology slides, but AI-predicted TILs have not yet been thoroughly validated as clinically relevant biomarker. Here we test whether AI-predicted TILs per HPF can be validated as an independent prognostic biomarker of CRC-specific survival in patients. We constructed an AI model to predict TILS per HPF using a weakly-supervised, transformer-based deep regression model, trained using 5-fold cross validation in a large dataset (n=1,738) and validated in a second independent dataset (n=223) of CRC cases. The model predicted TILs per HPF as a continuous variable, which was carried forward for survival analyses both as a continuous variable and dichotomized at a previously established <i>a priori<\/i> threshold of &#60;2 vs. &#8805;2 TILs per HPF. Using longitudinal data from the population-based Molecular Epidemiology of Colorectal Cancer Study (median follow-up = 95 months), survival analyses were performed using non-parametric and Cox-proportional hazards models, with and without adjustment for age, sex, ethnicity, stage, and molecularly measured microsatellite instability (MSI). Two or more AI-predicted TILs per HPF were significantly associated with 5-year CRC-specific survival (p=0.0000037), 5-year overall survival (p=0.00021), and overall survival (p=0.000067). In a Cox proportional hazards model adjusting for age, sex, ethnicity, stage, and MSI, &#8805;2 AI-predicted TILs per HPF was significantly associated with improved 5-year CRC-specific survival, with a hazard ratio (HR) = 0.62, (95% confidence interval; 0.43, 0.91), p=0.01.<br \/>Our new AI-driven deep learning model, which we call <i>HopeSTIL<\/i>, provides a highly efficient algorithm for analyzing digital pathology images of H&#38;E sections of CRC to quantify TILs per HPF. <i>HopeSTIL<\/i> is a validated prognostic marker for 5-year CRC-specific survival that does not require a pathologist to manually count and score TILs per HPF.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++BCS02-01 Artificial intelligence and machine\/deep learning,,"},{"Key":"Keywords","Value":"Deep learning,Tumor infiltrating lymphocytes,Survival,Microsatellite instability,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>S. B. Gruber<\/b><sup>1<\/sup>, O. S. M. El Nahhas<sup>2<\/sup>, J. D. Bonner<sup>1<\/sup>, J. K. Greenson<sup>3<\/sup>, D. Schmolze<sup>1<\/sup>, L. Shaktah<sup>1<\/sup>, J. Salazar<sup>1<\/sup>, L. Reynaga<sup>1<\/sup>, S. Lindsey<sup>1<\/sup>, J. Lu<sup>1<\/sup>, A. Mao<sup>1<\/sup>, V. Moreno<sup>4<\/sup>, S. L. Schmit<sup>5<\/sup>, Y.-Y. Tsai<sup>5<\/sup>, S. R. Hamilton<sup>1<\/sup>, G. Rennert<sup>6<\/sup>, J. N. Kather<sup>2<\/sup>; <br\/><sup>1<\/sup>City of Hope National Medical Center, Los Angeles, CA, <sup>2<\/sup>Technical University Dresden, Dresden, Germany, <sup>3<\/sup>University of Michigan, Ann Arbor, MI, <sup>4<\/sup>Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Spain, <sup>5<\/sup>Cleveland Clinic, Cleveland, OH, <sup>6<\/sup>Technion University, Haifa, Israel","CSlideId":"","ControlKey":"a6add2eb-82c1-49d8-95d4-3ed0637fc0ef","ControlNumber":"10485","DisclosureBlock":"<b>&nbsp;S. B. Gruber, <\/b> <br><b>Brogent International LLC<\/b> Other, Co-founder with equity. <br><b>O. S. M. El Nahhas, <\/b> <br><b>StratifAI<\/b> Other, Chief Executive Officer. <br><b>J. D. Bonner, <\/b> <br><b>Brogent International, LLC<\/b> Independent Contractor.<br><b>J. K. Greenson, <\/b> None..<br><b>D. Schmolze, <\/b> None..<br><b>L. Shaktah, <\/b> None..<br><b>J. Salazar, <\/b> None..<br><b>L. Reynaga, <\/b> None..<br><b>S. Lindsey, <\/b> None..<br><b>J. Lu, <\/b> None..<br><b>A. Mao, <\/b> None..<br><b>V. Moreno, <\/b> None..<br><b>S. L. Schmit, <\/b> None..<br><b>Y. Tsai, <\/b> None..<br><b>S. R. Hamilton, <\/b> None..<br><b>G. Rennert, <\/b> None.&nbsp;<br><b>J. N. Kather, <\/b> <br><b>StratifAI<\/b> Employment, Chief Scientific Officer.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10349","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"1","PosterboardNumber":"1","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB384","PresenterBiography":null,"PresenterDisplayName":"Stephen Gruber, MD;MPH;PhD","PresenterKey":"31776595-6202-40c6-9064-4b4ac04ec99b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB384. Artificial intelligence measures of tumor infiltrating lymphocytes predict colorectal cancer-specific and overall survival","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"592","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 3","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Artificial intelligence measures of tumor infiltrating lymphocytes predict colorectal cancer-specific and overall survival","Topics":null,"cSlideId":""},{"Abstract":"Tumor infiltrating lymphocytes (TILs)-based biomarkers have emerged as a robust method for predicting treatment efficacy and outcome in colorectal cancer (CRC). However, the quantification of TILs remains a strenuous task for pathologists and is susceptible to inter-pathologist variations. Deep learning (DL) can predict cancer biomarkers directly from routine hematoxylin and eosin (H&#38;E) pathology slides, enabling the automated and consistent quantification of TILs for clinical decision-making. Our study focuses on the prediction of TILs per high-power field (HPF) on two large cohorts of CRC patients. We developed a weakly-supervised, transformer-based deep regression model to predict TILs per HPF from routine H&#38;E-stained histology slides. We trained the model using 5-fold cross-validation on a large cohort of CRC patients (n=1,738), and validated its performance on an external cohort of CRC patients (n=223). The model was evaluated using the Pearson&#8217;s correlation coefficient r. Moreover, pathologist-determined TILs per HPF was categorized into low (&#60;2) and high (&#8805;2), enabling evaluation via the area under the receiver operating characteristic curve (AUROC). Our model achieved a significant correlation coefficient of 0.60 (p&#60;0.0001) for the predicted TILs per HPF in the holdout test sets of the internal cohort, and a significant correlation coefficient of 0.57 (p&#60;0.0001) on the external validation cohort. Using the thresholds for low and high TILs per HPF, we found that the model accurately predicted the presence of high TILs per HPF in both the internal and external test cohorts, yielding AUROCs of 0.76 and 0.81, respectively. These findings underscore the efficacy of our deep learning model in predicting TILs per HPF from routine pathology slides. This approach holds promise for cost-effective, efficient and uniform quantification of TILs per HPF in CRC, potentially across various cancer types.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++BCS02-01 Artificial intelligence and machine\/deep learning,,"},{"Key":"Keywords","Value":"Deep learning,Tumor infiltrating lymphocytes,Biomarkers,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>O. S. M. El Nahhas<\/b><sup>1<\/sup>, J. D. Bonner<sup>2<\/sup>, J. K. Greenson<sup>3<\/sup>, D. B. Schmolze<sup>2<\/sup>, L. Shaktah<sup>2<\/sup>, J. Salazar<sup>2<\/sup>, L. Reynaga<sup>2<\/sup>, S. Lindsey<sup>2<\/sup>, J. Lu<sup>2<\/sup>, V. Moreno<sup>4<\/sup>, S. L. Schmit<sup>5<\/sup>, Y.-Y. Tsai<sup>5<\/sup>, S. R. Hamilton<sup>2<\/sup>, G. Rennert<sup>6<\/sup>, J. N. Kather<sup>1<\/sup>, S. B. Gruber<sup>2<\/sup>; <br\/><sup>1<\/sup>Technical University of Dresden, Dresden, Germany, <sup>2<\/sup>City of Hope National Medical Center, Los Angeles, CA, <sup>3<\/sup>University of Michigan, Ann Arbor, MI, <sup>4<\/sup>Catalan Institute of Oncology, Hospitalet de Llobregat, Spain, <sup>5<\/sup>Cleveland Clinic, Cleveland, OH, <sup>6<\/sup>Technion University, Haifa, Israel","CSlideId":"","ControlKey":"4d215788-1455-42df-973b-a85b526acbb0","ControlNumber":"10820","DisclosureBlock":"<b>&nbsp;O. S. M. El Nahhas, <\/b> <br><b>StratifAI<\/b> Other, Chief Executive Officer. <br><b>J. D. Bonner, <\/b> <br><b>Brogent International LLC<\/b> Independent Contractor.<br><b>J. K. Greenson, <\/b> None..<br><b>D. B. Schmolze, <\/b> None..<br><b>L. Shaktah, <\/b> None..<br><b>J. Salazar, <\/b> None..<br><b>L. Reynaga, <\/b> None..<br><b>S. Lindsey, <\/b> None..<br><b>J. Lu, <\/b> None..<br><b>V. Moreno, <\/b> None..<br><b>S. L. Schmit, <\/b> None..<br><b>Y. Tsai, <\/b> None..<br><b>S. R. Hamilton, <\/b> None..<br><b>G. Rennert, <\/b> None.&nbsp;<br><b>J. N. Kather, <\/b> <br><b>StratifAI<\/b> Chief Scientific Officer. <br><b>S. B. Gruber, <\/b> <br><b>Brogent International LLC<\/b> Other, Co-founder with equity.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10351","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"2","PosterboardNumber":"3","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB386","PresenterBiography":null,"PresenterDisplayName":"Omar El Nahhas, BS;MS","PresenterKey":"e24ef8f5-900c-44f3-8459-3644cfcb81ab","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB386. Weakly-supervised prediction of tumor infiltrating lymphocytes per high power field from colorectal cancer histopathology slides using regression transformers","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"592","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 3","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Weakly-supervised prediction of tumor infiltrating lymphocytes per high power field from colorectal cancer histopathology slides using regression transformers","Topics":null,"cSlideId":""},{"Abstract":"Generated induced pluripotent stem cells (iPSCs) from the blood of patients with advanced gastric cancer, differentiating them into endothelial cells and fibroblasts. Utilizing microfluidic 3D cell culture, we intricately reconstructed the observed abnormal blood vessels in gastric cancer patients in a three-dimensional format, capturing real-time neovasculature. Applying deep learning techniques, we virtually labeled the growing blood vessels with fluorescence, unveiling thin and tortuous morphological characteristics specific to patient iPSCs, distinct from those derived from human umbilical cord endothelial cells. The development of a tumor model, vascularized with cancer cells from the same donor, establishes a versatile testbed for evaluating personalized cancer vascular models. Through comprehensive morphological and functional assessments, this platform facilitates screening for patient-specific combination therapies and holds promise as a model for immune response testing.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++BCS02-01 Artificial intelligence and machine\/deep learning,,"},{"Key":"Keywords","Value":"In vitro,Tumor neovasculature,Deep learning,Preclinical testing,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>J. Ko<\/b><sup>1<\/sup>, N. Jeon<sup>2<\/sup>, Y. Oh<sup>2<\/sup>; <br\/><sup>1<\/sup>Gachon University, Seongnam-si, Korea, Republic of, <sup>2<\/sup>Seoul National University, Seoul, Korea, Republic of","CSlideId":"","ControlKey":"11104373-0452-4768-b98d-b5ba35809439","ControlNumber":"10587","DisclosureBlock":"&nbsp;<b>J. Ko, <\/b> None.&nbsp;<br><b>N. Jeon, <\/b> <br><b>Qureator, Inc.<\/b> Stock.<br><b>Y. Oh, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10352","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"3","PosterboardNumber":"4","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB387","PresenterBiography":null,"PresenterDisplayName":"Jihoon Ko","PresenterKey":"7e338986-d871-40dc-a71e-23e61f372a0c","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB387. Microphysiological modeling of gastric cancer vasculature using iPSC-derived endothelial cells","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"592","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 3","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Microphysiological modeling of gastric cancer vasculature using iPSC-derived endothelial cells","Topics":null,"cSlideId":""},{"Abstract":"Abnormal activation of ALK, ROS1 and TRK is implicated in tumorigenesis, progression, invasion, and metastasis of malignancies through various mechanisms. The first generation TRK inhibitors including larotrectinib and entrectinib have limited applications due to acquired resistance in clinical settings. Multiple on-target mutations occur at the solvent-front, gatekeeper, and xDFG motif inside the ATP binding pocket of the TRK kinase domain. While some candidates under current clinical development aim to address the solvent-front mutation, they are ineffective against the xDFG mutations (e.g.NTRK1.G667X). There is strong unmet medical needs for next generation TRK inhibitors that can address resistance mutations. We employ the synergistic advantages of domain expertise and modern technology to accelerate early stage drug discovery. On our deep learning (DL) centric AI platform, extensive scientific computing supports large scale virtual screening, generative design, drug property prediction and multi-objective lead optimization. Only the optimized candidate compounds are passed along for synthesis and testing to save time and cost. In Ba\/F3-TPM3 cellular assays, LB-2159 showed superior potencies that are hundreds to thousands of fold higher than larotrectinib and\/or entrectinib, with IC50 values of 0.02 nM for NTRK1.WT, 0.3 nM for NTRK1.G595R and 0.88 nM for NTRK1.G667C. Similar cellular potencies were demonstrated for ALK and ROS1. In xenograft models LB-2159 at 10 mg\/kg bid resulted in complete tumor regression in Ba\/F3-TPM3-NTRK1-WT tumors, 96% TGI in Ba\/F3-TPM3-NTRK1-G595R tumors, 84% TGI and 100% survival in mice bearing Ba\/F3-TPM3-NTRK1-G667C tumors. The pharmacokinetic profiles of LB-2159 are overall favorable, demonstrating extended stability and half life. In vitro safety screens yielded clean profiles without any DDI signal or hERG liability. Preclinical safety evaluations exhibited good tolerance in rats. In multiple dose escalation studies LB-2159 was well tolerated at 50 mg\/kg\/day and beyond. Empowered by our proprietary AI platform, we have discovered the novel ALK\/ROS1\/TRK inhibitors that overcome clinically known resistance mutations. Our drug candidate exhibited good tolerance in animals in preclinical safety evaluations. In xenograft models that are resistant to current treatments the compound demonstrates strong tumor suppression efficacy. LB-2159 is advancing through IND enabling studies, and its preclinical profiles support the potential for best-in-class treatment for NTRK fusion-positive solid tumors.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++BCS02-01 Artificial intelligence and machine\/deep learning,,"},{"Key":"Keywords","Value":"Tyrosine kinase inhibitor,Solid tumors,Drug resistance,Deep learning,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>L. Xing<\/b>, J. Wang, W. Zhu; <br\/>LexBio, Suzhou, China","CSlideId":"","ControlKey":"d25e918b-248f-4b4a-ae2c-3bc695305d8d","ControlNumber":"9830","DisclosureBlock":"&nbsp;<b>L. Xing, <\/b> None..<br><b>J. Wang, <\/b> None..<br><b>W. Zhu, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10353","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"4","PosterboardNumber":"5","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB388","PresenterBiography":"","PresenterDisplayName":"Li Xing, PhD","PresenterKey":"20ddc5ea-064c-4f5b-b29a-b3c6377a889c","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB388. Super potent and efficacious ALK\/ROS1\/TRK inhibitor that overcomes multiple drug-resistant mutations","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"592","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 3","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Super potent and efficacious ALK\/ROS1\/TRK inhibitor that overcomes multiple drug-resistant mutations","Topics":null,"cSlideId":""},{"Abstract":"RET gene mutations and fusions are the driving events for the generation and deterioration of many cancer types. The first generation RET inhibitors, selpercatinib (Loxo-292) and pralsetinib (Blu-667), demonstrated clinically acquired resistance (e.g., solvent frontier mutations G810X, double mutations V804X-G810X etc.). Novel treatment that overcomes multiple resistance mutations is needed to improve patient outcomes. Leveraging our in-house AI technology platform, we have discovered the next generation RET inhibitors that overcome multiple resistance mutations including solvent front, gatekeeper and various double mutations. We employ the synergistic advantages of domain expertise and modern technology to accelerate early stage drug discovery. On our deep learning (DL) centric AI platform, extensive scientific computing supports large scale virtual screening, generative design, drug property prediction and multi-objective lead optimization. Only the optimized candidate compounds are passed along for synthesis and testing to save time and cost. In cell proliferation assays, our compound effectively inhibited KIF5B-RET Ba\/F3 WT, V804M, G810S, G810R, V804M-G810S with IC50 values of 0.4 nM, 1.3 nM, 1.1 nM, 3.4 nM, 6.3 nM, respectively, demonstrating significant improvement over selpercatinib in the range of several hundred fold in activities. Importantly, the compound is highly selective against VEGFR2, an off-target responsible for cardiovascular adverse effects in the approved RET inhibitors. The superior cellular potencies translated consistently into animal models. In Ba\/F3 KIF5B-RET-G810R xenograft model, treatment of 25 mg\/kg bid resulted in &#38;gt;90% TGI with a100% survival rate. The compound showed favorable pharmacokinetic properties, lack of drug-drug interaction (DDI), and devoid of hERG liability (IC50 &#38;gt; 10uM). Preclinical safety evaluations in rats exhibited good tolerance margin. We have discovered the second generation compound that potently inhibits a diverse range of RET alterations. The compound exhibits preferable pharmaceutical profiles and is advancing toward IND application.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++BCS02-01 Artificial intelligence and machine\/deep learning,,"},{"Key":"Keywords","Value":"RET,Solid tumors,Drug resistance,Deep learning,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>L. Xing<\/b>, W. Zhu, J. Wang; <br\/>LexBio Therapeutics, Suzhou, China","CSlideId":"","ControlKey":"00154acc-80c4-461f-b7d6-bc3761aaa77b","ControlNumber":"10284","DisclosureBlock":"&nbsp;<b>L. Xing, <\/b> None..<br><b>W. Zhu, <\/b> None..<br><b>J. Wang, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10354","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"5","PosterboardNumber":"6","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB389","PresenterBiography":"","PresenterDisplayName":"Li Xing, PhD","PresenterKey":"20ddc5ea-064c-4f5b-b29a-b3c6377a889c","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB389. Highly potent and selective RET inhibitor with robust anti-tumor activities against wild-type and acquired drug-resistant mutations","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"592","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 3","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Highly potent and selective RET inhibitor with robust anti-tumor activities against wild-type and acquired drug-resistant mutations","Topics":null,"cSlideId":""},{"Abstract":"Prostate cancer is distinguished by unique histological alterations in glandular architecture, observable in Whole Slide Images (WSIs). The disease is further characterized by pronounced genomic instability, exemplified by biomarkers such as DNA ploidy. While the Gleason Score effectively assesses the histological changes, the manual evaluation of DNA ploidy is subjective and time-consuming. Addressing the need for an objective diagnostic tool, our study developed a deep learning model aimed at accurately predicting DNA ploidy using publicly available WSI from the Cancer Genome Atlas (TCGA).<br \/>Utilizing a ResNet-18 convolutional neural network, we trained the model on WSIs from 200 TCGA patients to extract features and predict total mRNA expression. The model was further refined using data from 19 TCGA patients, focusing on ploidy number prediction. Comparative analysis against a random reference model revealed significant improvements of ploidy prediction in Mean Absolute Error (MAE) by 43.52%, Mean Absolute Percentage Error (MAPE) by 43.59%, and Mean Squared Error (MSE) by 67.86%. These enhancements were statistically validated (p-values: MAE - 7.07E-06, MAPE - 7.69E-06, MSE - 3.14E-05) and substantiated by large Cohen's d values (MAE - 2.88, MAPE - 2.86, MSE - 2.42), confirming the model's advanced predictive accuracy and practical utility.<br \/>This approach, validated further on a separate TCGA hold-out test set, signifies a major leap in prostate cancer diagnostics. By integrating mRNA prediction checkpoints, our model not only refines ploidy assessment but also sets the stage for correlating these predictions with patient clinical outcomes. These developments promise to enhance existing diagnostic methods, offering a more objective and efficient tool for DNA ploidy assessment in prostate cancer prognosis and treatment planning.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++BCS02-02 Digital pathology,,"},{"Key":"Keywords","Value":"Diagnostic marker,Prostate cancer,Deep learning,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>J. Vergara Cobos<\/b><sup>1<\/sup>, F. Carrillo-Perez<sup>2<\/sup>, M. Pizurica<sup>2<\/sup>, N. Andor<sup>3<\/sup>, O. Gevaert<sup>2<\/sup>; <br\/><sup>1<\/sup>Stanford University School of Medicine, Palo Alto, CA, <sup>2<\/sup>Stanford University, Palo Alto, CA, <sup>3<\/sup>Moffitt Cancer Center, Tampa, FL","CSlideId":"","ControlKey":"db9e1d43-21f8-422d-8179-19ab11115339","ControlNumber":"10717","DisclosureBlock":"&nbsp;<b>J. Vergara Cobos, <\/b> None..<br><b>F. Carrillo-Perez, <\/b> None..<br><b>M. Pizurica, <\/b> None..<br><b>N. Andor, <\/b> None..<br><b>O. Gevaert, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10355","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"6","PosterboardNumber":"7","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB390","PresenterBiography":null,"PresenterDisplayName":"Josselyn Sofia Vergara Cobos","PresenterKey":"d2f43036-4f16-4a7c-b95f-9ad730ed2517","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB390. Enhancing prostate cancer diagnosis: A deep learning approach for DNA ploidy prediction from whole slide images","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"592","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 3","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Enhancing prostate cancer diagnosis: A deep learning approach for DNA ploidy prediction from whole slide images","Topics":null,"cSlideId":""},{"Abstract":"Background: Cancers with homologous recombination deficiency (HRD) can benefit from platinum salts and PARP inhibitors. Standard diagnostic tests, including FDA-approved companion diagnostics, for detecting HRD require molecular profiling, which is not universally available with global testing rates lowest among minority, rural, and other underserved populations.<br \/>Methods: We trained DeepHRD, a deep-learning platform for predicting HRD from hematoxylin and eosin (H&#38;E)-stained histopathological slides, using primary breast (n=1,008) and ovarian (n=459) cancers from The Cancer Genome Atlas (TCGA). DeepHRD was compared to four standard HRD molecular tests using breast (n=349) and ovarian (n=141) cancers from multiple external and independent datasets, including clinical cohorts with platinum complete response, progression-free survival (PFS) and overall survival (OS) endpoints.<br \/>Results: DeepHRD detected HRD from held-out H&#38;E-stained breast cancer slides in TCGA with an AUC of 0.81 ([0.77-0.85]; 95% confidence interval). This performance was confirmed in two independent primary breast cancer cohorts (AUC=0.76; [0.71-0.82]). In an external platinum-treated metastatic breast cancer cohort, samples detected as HRD had a higher complete response (AUC=0.76; [0.54-0.93]) with 3.7-fold increase in median PFS (14.4 versus 3.9 months; p-value=0.0019) and hazard ratio (HR) of 0.45 (p=0.0047) after correcting for PAM50 molecular subtype and age at diagnosis. This deep-learning classifier outperformed four genomic HRD tests used in the clinic, including standard HRD score, <i>BRCA1\/2<\/i>, 26-HR gene panel and single-base substitution signature 3 (SBS3). Multiresolution spatial mapping identified morphological features utilized by DeepHRD for detecting HRD, notably enriched for neoplastic and necrotic tissues, and a higher macrophage density. Through transfer learning to high-grade serous-ovarian cancer, DeepHRD-positive samples exhibited better overall survival after TCGA first-line (HR=0.46; p=0.030) and an external neoadjuvant (HR=0.49; p=0.015) platinum-treated cohorts.<br \/>Conclusion: In summary, DeepHRD exhibits consistent hazard ratios ranging from 0.45 to 0.49 across the three clinical cohorts and captures 1.8- to 3.1-fold more HRD-positive breast and ovarian cancer patients. DeepHRD-positive breast cancer patients that received platinum exhibited better complete response and PFS. Similarly, DeepHRD-positive platinum-treated ovarian cancer patients had a better OS. DeepHRD&#8217;s ability to detect HRD from digital H&#38;E slides provides an important precision oncology tool that can be utilized in resource-constrained and underserved areas where genomic testing is generally not existent.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++BCS02-02 Digital pathology,,"},{"Key":"Keywords","Value":"Homologous recombination,Deep learning,Treatment response,Digital pathology,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>E. N. Bergstrom<\/b><sup>1<\/sup>, A. Abbasi<sup>1<\/sup>, M. Diaz-Gay<sup>1<\/sup>, L. Galland<sup>2<\/sup>, S. Ladoire<sup>2<\/sup>, S. M. Lippman<sup>1<\/sup>, L. B. Alexandrov<sup>1<\/sup>; <br\/><sup>1<\/sup>UC San Diego, San Diego, CA, <sup>2<\/sup>Centre Georges-Fran√ßois Leclerc, Dijon, France","CSlideId":"","ControlKey":"68645416-1af9-4632-af42-51d0a9996999","ControlNumber":"10746","DisclosureBlock":"&nbsp;<b>E. N. Bergstrom, <\/b> None..<br><b>A. Abbasi, <\/b> None..<br><b>M. Diaz-Gay, <\/b> None..<br><b>L. Galland, <\/b> None..<br><b>S. Ladoire, <\/b> None.&nbsp;<br><b>S. M. Lippman, <\/b> <br><b>io9, LLC<\/b> Other, Co-founder and has equity interest. <br><b>L. B. Alexandrov, <\/b> <br><b>io9, LLC<\/b> Other, Compensated consultant and has equity interest. <br><b>Biotheranostics, Inc<\/b> Other, Spouse is an employee.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10356","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"7","PosterboardNumber":"8","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB391","PresenterBiography":null,"PresenterDisplayName":"Erik Bergstrom","PresenterKey":"8f202229-be27-431b-b5ee-9f14cb74e3c0","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB391. Deep learning AI predicts HRD and platinum response from histologic slides","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"592","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 3","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Deep learning AI predicts HRD and platinum response from histologic slides","Topics":null,"cSlideId":""},{"Abstract":"<b>Purpose:<\/b> Pathologists routinely analyze H&#38;E-stained FFPE tissue slides microscopically to arrive at diagnoses for patients. Pathomics, the study of quantitative imaging from such samples, aims to elevate diagnostic accuracy by revealing intricate tissue and cellular details. Our research evaluates how pathomic features from tissue imagery can predict gene expression, as determined by RNA sequencing, offering advancements in the molecular profiling and targeted therapy for invasive breast carcinoma (IBC).<br \/><b>Method:<\/b> We conducted an analysis of 90 regions of interest (ROIs) on FFPE tissue slide images from the TCGA registry for patients with IBC. Using HistomicsTK software, we extracted nearly 300 pathomic features depicting cell morphometry, intensity, and gradient from these regions of interest (ROIs). We then assessed the intra-correlation of the pathomic features within the ROIs of the same tissue slide to identify the most heterogeneous and highly correlating features (n=20) across categories&#8212;morphometry, intensity, and gradient&#8212;with a Pearson&#700;s Correlation coefficient (r) greater than 0.9 and a FDR adjusted p-value less than 0.05. Subsequently, gene expression data in the form of FPKM were obtained for the corresponding tissues from TCGA. We trained a Multitask Elastic Net (MTEN) model on these pathomic features using an 80:20 split for the training and testing sets, with a three-fold cross-validation applied to the training set utilizing ImaGene software. The model's performance was evaluated by measuring the AUC and R&#178; value for the predicted gene expression on the testing set.<br \/><b>Result and Biological significance<\/b>: The testing of the MTEN model using a testing set predicted the expression of three genes identified in the literature as prognostic markers in breast cancer, namely ALDH1L2, MFAP5, and MXRA8, with an AUC greater than 0.8 and an R&#178; above 0.5 at a p-value of less than 0.002. According to the literature, expression of genes from the ALDH1 superfamily in breast cancer correlates with the stage of the disease, triple-negative status, and response to neoadjuvant therapy. The upregulation of MFAP5 in invasive breast carcinomas has been associated with high risk prognostic features, such as higher tumor grade and stage and increased angiogenesis, and poorer outcomes, such as lymph node metastasis. Furthermore, MXRA8 is involved in modulating the progression of human triple-negative breast cancer, likely through its influence on the interactions of tumor cells with their microenvironment.<br \/><b>Conclusion:<\/b> The present study predicts the expression of clinically relevant genes in IBC using a heterogeneous set of pathomic features extracted from FFPE tissue slide imagery. By linking cell and tissue-based morphometric, intensity, and gradient features with gene expression, researchers can gain insights into the molecular mechanisms underlying disease progression. Digital pathology and pathomics may reduce the need for additional genetic testing in critical patient-cases by providing predictive information from routinely acquired pathology slides. Bridging the gap between phenotypic tissue data and molecular data, the predictive capabilities of pathomic features represent a significant advancement in the field of precision medicine.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++BCS02-02 Digital pathology,,"},{"Key":"Keywords","Value":"Machine learning,Digital Pathology,Pathomics,Gene expression,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>S. S. Sukhadia<\/b><sup>1<\/sup>, D. Yadav<sup>2<\/sup>, K. E. Muller<sup>1<\/sup>; <br\/><sup>1<\/sup>Dartmouth Hitchcock Medical Center, Lebanon, NH, <sup>2<\/sup>Dartmouth College, Lebanon, NH","CSlideId":"","ControlKey":"27b8106f-6808-4493-8e86-dc7b385d82f0","ControlNumber":"10528","DisclosureBlock":"&nbsp;<b>S. S. Sukhadia, <\/b> None..<br><b>D. Yadav, <\/b> None..<br><b>K. E. Muller, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10357","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"8","PosterboardNumber":"9","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB392","PresenterBiography":null,"PresenterDisplayName":"Shrey Sukhadia, MS","PresenterKey":"c04f3956-681e-4587-9d15-1d40e00a0a3b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB392. Transformative pathomics in oncology: Harnessing FFPE tissue slide imagery for clinically relevant gene expression prediction in invasive breast carcinoma","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"592","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 3","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Transformative pathomics in oncology: Harnessing FFPE tissue slide imagery for clinically relevant gene expression prediction in invasive breast carcinoma","Topics":null,"cSlideId":""},{"Abstract":"<b>Introduction: <\/b>Colorectal cancer (CRC) ranks second in cancer morbidity, with approximately 60% of patients being diagnosed at an advanced stage. Here, we apply a multiomic strategy jointly leveraging plasma cell-free DNA (cfDNA) and multiple extracellular vesicle (EV)-derived analytes to enhance CRC diagnostic accuracy.<br \/><b>Materials and Methods: <\/b>Plasma was collected from 96 individuals, 48 CRC patients (stage II-IV) and 48 CRC-negative healthy controls. EVs and cfDNA were isolated from the same plasma sample to look at complementary information within the sample. We developed an EV RNA sequencing platform targeting mRNAs and long non-coding RNAs and sequenced to a depth of 50M reads per sample; cfDNA methylome profiling was sequenced to an equivalent depth. The Olink platform profiled proteins both directly from plasma and from isolated EVs. Expression of EV-derived RNA, splice variants, and proteins in addition to cfDNA methylation patterns were analyzed using Bio-Techne&#8217;s multiomic platform. Machine learning-based feature selection algorithms identified biomarker signatures from each analyte. Receiver-operator characteristic curves (ROC) were generated utilizing leave-one-out cross-validation of na&#239;ve Bayes classifier models to compute the area under the curve (AUC). Individual signatures were integrated to generate a multiomic classifier.<br \/><b>Results: <\/b>Differential gene expression (DEx) analysis identified ~1000 DEx genes with significant enrichment of CRC-relevant pathways. Splice variant analysis identified several genes previously implicated in CRC with differential isoform usage. Over 1.7 million differentially methylated bases were detected between CRC-positive and CRC-negative cohorts. Segmentation of the genome using out-of-bag reference data yielded ~1100 genomic segments, many of which overlap previously reported CRC biomarkers and identified unique information about the CRC status. Proteomic analysis identified several differentially abundant markers with high discriminatory power. Following feature selection analysis, AUCs obtained from top 10 features of RNA expression, splice variants, cfDNA methylation, and protein abundance with an integrative analysis identified a multi-analyte signature, with an overall AUC of 0.99.<br \/><b><\/b><b>Conclusion: <\/b>While biomarker signatures obtained from each analyte in this study resulted in effective separation of CRC status, the multiomic signature further improved the discriminatory power&#8212;underscoring the complementary nature of the signals. Thus, a multiomic biomarker discovery strategy leveraging cfDNA and EV cargo holds tremendous promise for minimally invasive screening and potential detection of early-stage cancers, which is currently under further investigation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++BCS02-06 Liquid biopsy: Multi-analyte and multi-omic,,"},{"Key":"Keywords","Value":"Liquid biopsies,Multiomics,Exosomes,Colorectal cancer,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>K. Manning<\/b><sup>1<\/sup>, D. Miller<sup>1<\/sup>, Y. Yang<sup>1<\/sup>, J. Cole<sup>1<\/sup>, S. Xing<sup>1<\/sup>, C. Benway<sup>1<\/sup>, C. Ray<sup>1<\/sup>, S. Chakrabortty<sup>1<\/sup>, B. Haynes<sup>2<\/sup>, S. Yu<sup>1<\/sup>, J. Skog<sup>1<\/sup>; <br\/><sup>1<\/sup>Exosome Diagnostics, a Bio-techne brand, Waltham, MA, <sup>2<\/sup>Asuragen, a Bio-techne brand, Austin, TX","CSlideId":"","ControlKey":"98a8a5f2-faa0-457e-ab45-cdd5df485607","ControlNumber":"10711","DisclosureBlock":"&nbsp;<b>K. Manning, <\/b> None..<br><b>D. Miller, <\/b> None..<br><b>Y. Yang, <\/b> None..<br><b>J. Cole, <\/b> None..<br><b>S. Xing, <\/b> None..<br><b>C. Benway, <\/b> None..<br><b>C. Ray, <\/b> None..<br><b>S. Chakrabortty, <\/b> None..<br><b>B. Haynes, <\/b> None..<br><b>S. Yu, <\/b> None..<br><b>J. Skog, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10358","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"9","PosterboardNumber":"10","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB393","PresenterBiography":null,"PresenterDisplayName":"Kyle Manning","PresenterKey":"a1ad5ad3-a02c-4795-839c-ebaf8e38cee7","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB393. Exosome based multiomics combined with cfDNA methylation reveals complementary signatures in blood based liquid biopsy that carry promise for minimally invasive colorectal cancer screening","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"592","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 3","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Exosome based multiomics combined with cfDNA methylation reveals complementary signatures in blood based liquid biopsy that carry promise for minimally invasive colorectal cancer screening","Topics":null,"cSlideId":""},{"Abstract":"<b>Background<\/b>Aromatase inhibitors (AIs) are commonly used in the management of estrogen receptor-positive (ER+) breast cancer as they effectively reduce estrogen levels which inhibits tumor growth and recurrence. Aromatase inhibitors are increasingly used in selected patients as neoadjuvant therapy.<br \/><b>Clinical trial<\/b>The NEOLETEXE is a neoadjuvant, randomized, open-label, intra-patient, cross-over, single-center phase II clinical trial, aimed to treat postmenopausal patients with locally advanced breast cancer. Most patients presented large T3\/T4 tumors and\/or N2\/N3 involvement. Patients were randomly assigned to neoadjuvant therapy with either letrozole (2.5 mg daily) or exemestane (25 mg daily) for 3 months followed by a cross-over to the alternative AI for another 3 months followed by surgery. A total of 102 patients were enrolled in the NEOLETEXE trial.<br \/><b>Aim of the study<\/b>We aimed to compare clones derived from bulk exome sequencing with single-cell analyses at DNA and RNA level from the same tumors at different time points of treatment in order to characterize evolutionary trajectories of cancer and immune cells in 23 patients at scRNA level and 16 patients at scDNA level from the NEOLETEXE trial.<br \/><b>Methods<\/b>Tumor biopsies taken before treatment (baseline) at crossover (after 3 months) and end of neoadjuvant therapy (after 6 months), were analyzed by single-cell DNA (MissionBio) and scRNA (10xGenomics), T cell receptor (TCR), and B cell receptor (BCR) sequencing.<br \/><b>Results <\/b>We employed the The Mission Bio Tapestri Platform, which enables targeted scDNAseq of nuclei isolated from fresh frozen tumor tissue using microfluid droplet technology. A custom panel of 497 amplicons covering 528 sequence variants was designed to study treatment response selected by the following criteria: 1) Up to 10 mutations from each sublonal clusters defined by analysing 32 samples (3 time points) from 11 NeoLetExe patients with whole exome sequencing (WES) data prioritizing mutations in genes part of the Cancer Gene Census (COSMIC), 2) known mutations covering all chromosomes to enable CNV analysis and 3) &#8220;Hand-picked&#8221; mutations with significance for breast cancer (e.g. hotspot <i>ESR1<\/i> mutations). We performed SNV and CNV analysis and reconstruction of mutational lineages with user developed tools. On average, 81% of the clusters defined by WES was validated by scDNAseq and copy number profiles matching between the two data sets. Fishplot with variants defining cell clusters in WES using data from scDNAseq show clonal development during treatment.The scRNA analyses revealed cell types were identified through clustering of the scRNA data. We focused on the epithelial cells to first distinguish between the normal and malignant epithelial cells using the InferCNV algorithm. We next examined CD4, CD8, NK cells, and macrophages, using RNA velocity and diffusion pseudotime using CellRank and scVelo to delineate the differentiation trajectories of immune cell types.<br \/><b>Conclusions<\/b> We created a detailed map that provides a high-resolution view of the diverse clones and cell types present in tumor biopsies from the NEOLETEXE trial. We characterize the impact of therapies on the evolutionary dynamics of both cancer and immune cells. Our analyzes sought insights into the underlying factors that contribute to the sensitivity and resistance to aromatase inhibitors.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++BCS02-08 Network biology and precision medicine,,"},{"Key":"Keywords","Value":"Heterogeneity,Hormone receptors,Single cell,Bioinformatics,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>V. N. Kristensen<\/b><sup>1<\/sup>, G. I. G. Alnaes<sup>2<\/sup>, P. Vernhoff<sup>2<\/sup>, L. Schmiester<sup>3<\/sup>, S. Ghannoum<sup>2<\/sup>, M. Fongaard<sup>4<\/sup>, P. M. Bjornstad<sup>2<\/sup>, K. Selsaas<sup>5<\/sup>, S. Geisler<sup>6<\/sup>, M. Seyedzadeh<sup>7<\/sup>, U.-C. Buvarp<sup>6<\/sup>, T. Luders<sup>8<\/sup>, D. Lambrechts<sup>9<\/sup>, M. Lyngra<sup>10<\/sup>, A. Frigessi<sup>3<\/sup>, X. Tekpli<sup>8<\/sup>, J. Geilser<sup>6<\/sup>; <br\/><sup>1<\/sup>University of Oslo, Institute of Clinical Medicine, Faculty of Medicine, Oslo, Norway, <sup>2<\/sup>Oslo University Hospital, Department of Medical Genetics, Oslo, Norway, <sup>3<\/sup>University of Oslo, Oslo Centre for Biostatistics and Epidemiology (OCBE), Oslo, Norway, <sup>4<\/sup>Oslo University Hospital, Depsrtment of Medical Genetics, Oslo, Norway, <sup>5<\/sup>Department of Breast and Endocrine Surgery, Akershus University Hospital, Oslo, Norway, <sup>6<\/sup>Department of Oncology, Akershus University Hospital, Oslo, Norway, <sup>7<\/sup>Department of Radiology, Akershus University Hospital, Oslo, Norway, <sup>8<\/sup>Oslo University Hospital, Institute for Cancer Research, Oslo, Norway, <sup>9<\/sup>Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium, <sup>10<\/sup>Department of Pathology, Akershus University Hospital, Oslo University Hospital, Institute for Cancer Research, Oslo, Norway","CSlideId":"","ControlKey":"f074087a-99d5-4736-9cdb-be73f1e7b4e0","ControlNumber":"10792","DisclosureBlock":"&nbsp;<b>V. N. Kristensen, <\/b> None..<br><b>G. I. G. Alnaes, <\/b> None..<br><b>P. Vernhoff, <\/b> None..<br><b>L. Schmiester, <\/b> None..<br><b>S. Ghannoum, <\/b> None..<br><b>M. Fongaard, <\/b> None..<br><b>P. M. Bjornstad, <\/b> None..<br><b>K. Selsaas, <\/b> None..<br><b>S. Geisler, <\/b> None..<br><b>M. Seyedzadeh, <\/b> None..<br><b>U. Buvarp, <\/b> None..<br><b>T. Luders, <\/b> None..<br><b>D. Lambrechts, <\/b> None..<br><b>M. Lyngra, <\/b> None..<br><b>A. Frigessi, <\/b> None..<br><b>X. Tekpli, <\/b> None..<br><b>J. Geilser, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10359","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"10","PosterboardNumber":"11","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB394","PresenterBiography":null,"PresenterDisplayName":"Vessela Kristensen, PhD","PresenterKey":"2bf55caa-3096-49d0-bf1d-59c63ebdd474","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB394. <b><\/b>Tumor evolution upon treatment pressure with aromatase inhibitors in locally advanced estrogen receptor positive breast cancer <b><\/b>","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"592","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 3","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"<b><\/b>Tumor evolution upon treatment pressure with aromatase inhibitors in locally advanced estrogen receptor positive breast cancer <b><\/b>","Topics":null,"cSlideId":""},{"Abstract":"CRISPR-Cas9, a highly effective gene editing tool, is a molecular scissor that induces double strand breaks (DSBs) at its targeted genomic locations. Ionizing radiation (IR), in contrast, generates DSBs and other DNA lesions, making it potentially more toxic than CRISPR-Cas9 induced DSBs. Alternatively, CRISPR-Cas9 might be more toxic as the Cas9 activity would continue if the DSB were repaired to wild type, resulting in more scissions per target. We designed multitarget sgRNAs targeting 0-16 sites in the human genome and performed similar dose-response experiments with IR (0-10 Gy) over 21 days on two pancreatic cancer (PC) cell lines. Growth inhibition was measured through clonogenicity and alamarBlue assays, and &#947;-H2AX staining performed to calculate DSBs. Surviving colonies from sgRNA transduction underwent whole genome sequencing (WGS) and targeted deep sequencing to quantify mutations. Cell growth was assessed through cell counting and sgRNA tag survival over time. Chromosomal changes were elucidated through chromosome breakage assays and XY FISH. We found that cytotoxicity increased as a function of both IR dose and number of sgRNA target site. At a comparable number of DSBs, CRISPR-Cas9 demonstrated higher cytotoxicity (~44% growth inhibition from 5-target sgRNA, ~15 &#947;-H2AX foci in the PC cells) compared to IR (9% inhibition from 0.5 Gy, ~25 foci). WGS of 5-cutter treated cells also revealed ~13 CRISPR-Cas9 induced DSBs in the PC cells. &#62;99% cytotoxicity was achieved with 12-target sgRNA and 8 Gy. Moreover, sequencing of surviving colonies from sgRNA-treated cells confirmed lack of widespread off-target events. Notably, no surviving colonies could be obtained from the 12- and 16-cutter treated Panc10.05 cells and 8-14 cutters treated TS0111 cells.Both CRISPR-Cas9 and IR assays demonstrated delayed cell death, and cell death began 7 days after transduction of multitarget sgRNAs. Cytogenetic analyses on cells transduced with a 14-cutter sgRNA over 21 days revealed accumulation of karyotypic abnormalities peaking at day 14, and polyploidization peaking at day 10 and decreasing by day 21. Structural variant (SV) analyses from WGS data showed that the number of SVs per colony increased and peaked in 6-cutter colonies (average = 42 SVs), then decreased in 8- and 14-cutter colonies. Finally, surviving colonies that were resistant to 5-, 8-, and 16-cutter sgRNAs were re-challenged with their original multitarget sgRNA, 12-, and 14-cutter sgRNAs. Re-treating with original sgRNA showed no growth inhibition, while &#62;95% cytotoxicity was observed by re-challenging them with 12- or 14-cutter sgRNAs.In conclusion, CRISPR-Cas9 kills pancreatic cancers by inducing chromosomal catastrophe, and resistance to original set of CRISPR-Cas9 induced DSBs can be easily overcome by targeting different sites. For the same number of DSBs, CRISPR-Cas9 was surprisingly more toxic than IR.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++BCS02-10 Other,,"},{"Key":"Keywords","Value":"CRISPR\/Cas9,Ionizing radiation,DNA double-strand break,Chromosomal instability,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>S. K. Teh<\/b>, A. Kotwal, E. Halper-Stromberg, L. Morsberger, K. Bowland, A. Bennett, M. Goldstein, Y. S. Zou, J. R. Eshleman; <br\/>Johns Hopkins University School of Medicine, Baltimore, MD","CSlideId":"","ControlKey":"511ac5ee-21a0-48c7-a3a8-1457b36e95f2","ControlNumber":"10823","DisclosureBlock":"&nbsp;<b>S. K. Teh, <\/b> None..<br><b>A. Kotwal, <\/b> None..<br><b>E. Halper-Stromberg, <\/b> None..<br><b>L. Morsberger, <\/b> None..<br><b>K. Bowland, <\/b> None..<br><b>A. Bennett, <\/b> None..<br><b>M. Goldstein, <\/b> None..<br><b>Y. S. Zou, <\/b> None..<br><b>J. R. Eshleman, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10362","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"11","PosterboardNumber":"14","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB397","PresenterBiography":null,"PresenterDisplayName":"Selina Shiqing Teh, BS,PhD","PresenterKey":"12b46e6a-7d58-4042-8ed0-b142138df8b2","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB397. Simultaneous CRISPR-Cas9 induced double strand breaks causes chromosomal catastrophe in pancreatic cancers: A parallel comparison with ionizing radiation","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"592","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 3","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Simultaneous CRISPR-Cas9 induced double strand breaks causes chromosomal catastrophe in pancreatic cancers: A parallel comparison with ionizing radiation","Topics":null,"cSlideId":""}]